drugset / Trial / NCT01661335
Efficacy of Aprepitant (Emend®) in Children
RandomizedCrossoverTriple-blindPrevention
Summary
The purpose of this study is to find out whether or not adding aprepitant(Emend®) to the standard therapy will help children who receive chemotherapy to have less nausea and vomiting.
Timeline
- Start
- 2012-06-01
- Primary completion
- 2017-06-29
- Completion
- 2017-06-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aprepitant | Other / unclassified | 2 mg/kg | Oral |
| Subject | Dexamethasone | Small molecule | 0.2 mg/kg | Intravenous |
| Subject | Dexamethasone | Small molecule | 0.4 mg/kg | Intravenous |
| Background | Ondansetron | Other / unclassified | 0.15 mg/kg | Intravenous |